Discontinuation of First-Line Disease-Modifying Therapy in Patients With Stable Multiple Sclerosis

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1. 1Pre-analytical stability of serum biomarkers for neurological disease: neurofilament-light, glial fibrillary acidic protein and contactin-12022 · 52 citations
2. 2Age-related gadolinium-enhancement of MRI brain lesions in multiple sclerosis2005 · 69 citations
3. 3The Multiple Sclerosis Impact Scale (MSIS-29): A new patient-based outcome measure2001 · 1,122 citations
4. 4The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection.1992 · 34,001 citations
5. 5Discontinuation of disease-modifying therapy for patients with relapsing-remitting multiple sclerosis: Effect on clinical and MRI outcomes2019 · 49 citations